JP6434523B2 - カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する - Google Patents
カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する Download PDFInfo
- Publication number
- JP6434523B2 JP6434523B2 JP2016545265A JP2016545265A JP6434523B2 JP 6434523 B2 JP6434523 B2 JP 6434523B2 JP 2016545265 A JP2016545265 A JP 2016545265A JP 2016545265 A JP2016545265 A JP 2016545265A JP 6434523 B2 JP6434523 B2 JP 6434523B2
- Authority
- JP
- Japan
- Prior art keywords
- arg
- lys
- aromatic
- phe
- dmt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims 3
- 231100000419 toxicity Toxicity 0.000 title claims 2
- 230000001988 toxicity Effects 0.000 title claims 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 206010012239 Delusion Diseases 0.000 claims 6
- 230000001149 cognitive effect Effects 0.000 claims 6
- 231100000868 delusion Toxicity 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 3
- 206010027951 Mood swings Diseases 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 230000016571 aggressive behavior Effects 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- 230000003252 repetitive effect Effects 0.000 claims 3
- 230000035807 sensation Effects 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229940095064 tartrate Drugs 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 230000001755 vocal effect Effects 0.000 claims 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 230000006974 Aβ toxicity Effects 0.000 claims 1
- 102000004020 Oxygenases Human genes 0.000 claims 1
- 108090000417 Oxygenases Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361884722P | 2013-09-30 | 2013-09-30 | |
| US61/884,722 | 2013-09-30 | ||
| PCT/US2014/058049 WO2015048647A1 (en) | 2013-09-30 | 2014-09-29 | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210325A Division JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533392A JP2016533392A (ja) | 2016-10-27 |
| JP2016533392A5 JP2016533392A5 (https=) | 2017-11-09 |
| JP6434523B2 true JP6434523B2 (ja) | 2018-12-05 |
Family
ID=52744565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545265A Expired - Fee Related JP6434523B2 (ja) | 2013-09-30 | 2014-09-29 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
| JP2018210325A Withdrawn JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210325A Withdrawn JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160375088A1 (https=) |
| EP (1) | EP3052115A4 (https=) |
| JP (2) | JP6434523B2 (https=) |
| CN (1) | CN106163537A (https=) |
| AU (2) | AU2014324580B2 (https=) |
| CA (1) | CA2925757A1 (https=) |
| WO (1) | WO2015048647A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052115A4 (en) * | 2013-09-30 | 2017-09-27 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
| WO2015095077A1 (en) * | 2013-12-16 | 2015-06-25 | Cornell University | Methods and compositions for treating and preventing cognitive dysfunction |
| CA3020393A1 (en) * | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| CN107320711A (zh) * | 2017-03-24 | 2017-11-07 | 南京大学 | 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用 |
| AU2020368789B2 (en) * | 2019-10-16 | 2024-01-18 | Naturesense Co., Ltd. | Peptide for improving memory and preventing or alleviating cognitive impairment, composition containing same and preparation method therefor |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1307219A4 (en) * | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
| CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| CA2851972C (en) * | 2004-01-23 | 2015-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| CA2947335A1 (en) * | 2005-09-16 | 2007-03-29 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
| AU2012271691A1 (en) * | 2011-06-14 | 2014-01-16 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| EP3052115A4 (en) * | 2013-09-30 | 2017-09-27 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
-
2014
- 2014-09-29 EP EP14848640.0A patent/EP3052115A4/en not_active Withdrawn
- 2014-09-29 JP JP2016545265A patent/JP6434523B2/ja not_active Expired - Fee Related
- 2014-09-29 AU AU2014324580A patent/AU2014324580B2/en not_active Ceased
- 2014-09-29 CN CN201480063400.5A patent/CN106163537A/zh active Pending
- 2014-09-29 WO PCT/US2014/058049 patent/WO2015048647A1/en not_active Ceased
- 2014-09-29 CA CA2925757A patent/CA2925757A1/en not_active Abandoned
- 2014-09-29 US US15/025,612 patent/US20160375088A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210325A patent/JP2019052158A/ja not_active Withdrawn
-
2020
- 2020-05-25 AU AU2020203424A patent/AU2020203424A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014324580B2 (en) | 2020-02-27 |
| AU2020203424A1 (en) | 2020-06-11 |
| JP2019052158A (ja) | 2019-04-04 |
| CN106163537A (zh) | 2016-11-23 |
| JP2016533392A (ja) | 2016-10-27 |
| EP3052115A4 (en) | 2017-09-27 |
| EP3052115A1 (en) | 2016-08-10 |
| AU2014324580A1 (en) | 2016-04-21 |
| WO2015048647A1 (en) | 2015-04-02 |
| CA2925757A1 (en) | 2015-04-02 |
| US20160375088A1 (en) | 2016-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019052158A (ja) | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する | |
| JP2019069985A (ja) | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する | |
| JP6480921B2 (ja) | コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用 | |
| JP2016000750A (ja) | 芳香族カチオン性ペプチドおよびその使用 | |
| CN102791280A (zh) | 用于预防或治疗血管阻塞损伤的方法 | |
| CN103830719A (zh) | 用于进行冠状动脉旁路移植手术的方法 | |
| CA2916492A1 (en) | Peptide therapeutics and methods for using same | |
| JP2018076337A (ja) | 芳香族陽イオン性ペプチドおよびその使用 | |
| EP3501532A2 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| EP3502132A1 (en) | Therapeutic compositions including therapeutic small molecules and uses thereof | |
| WO2015183984A2 (en) | Therapeutic compositions including tocopherol and uses thereof | |
| JP2017203036A (ja) | 芳香族カチオン性ペプチド及びその使用 | |
| WO2016004441A1 (en) | Methods for the prevention or treatment of acute myocardial infarction injury | |
| HK1178086A (en) | Methods for the prevention or treatment of vessel occlusion injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170926 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180903 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181009 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6434523 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |